These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30712391)

  • 1. Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials.
    Birkhaeuser M; Bitzer J; Braat S; Ramos Y
    Climacteric; 2019 Jun; 22(3):312-322. PubMed ID: 30712391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.
    Hitchcock CL; Prior JC
    Menopause; 2012 Aug; 19(8):886-93. PubMed ID: 22453200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.
    Takamatsu K; Miki T; Miyazaki K; Hashimoto A; He W; Wang X
    Climacteric; 2024 Aug; 27(4):389-397. PubMed ID: 38864290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
    Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
    J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
    Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.
    Ivgy-May N; Hajak G; van Osta G; Braat S; Chang Q; Roth T
    J Clin Sleep Med; 2020 Sep; 16(9):1455-1467. PubMed ID: 32351205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
    Simon JA; Portman DJ; Kaunitz AM; Mekonnen H; Kazempour K; Bhaskar S; Lippman J
    Menopause; 2013 Oct; 20(10):1027-35. PubMed ID: 24045678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
    Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
    Int J Gynaecol Obstet; 2024 Sep; 166(3):969-983. PubMed ID: 38563867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
    Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
    Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
    Simon JA; Gaines T; LaGuardia KD;
    Menopause; 2016 Nov; 23(11):1214-1221. PubMed ID: 27760081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.